OTCMKTS:AGYTF Allergy Therapeutics (AGYTF) Stock Price, News & Analysis → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free AGYTF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range N/A52-Week Range$0.17▼$0.19VolumeN/AAverage VolumeN/AMarket Capitalization$13.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesShort InterestStock AnalysisHeadlinesShort Interest Get Allergy Therapeutics alerts: Email Address Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Allergy Therapeutics Stock (OTCMKTS:AGYTF)Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.Read More Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. AGYTF Stock News HeadlinesMay 23, 2024 | finance.yahoo.comTheranica: 1 IN 4 ADOLESCENTS SUFFER FROM MIGRAINE DISEASE AND ARE AT RISK FOR LONG-TERM DISABILITYMay 16, 2024 | msn.comTONIGHT AT 5:30: Is full-time travel cheaper than your mortgage or rent?May 16, 2024 | investing.comAllergy Therapeutics PLC (AGYA)May 14, 2024 | markets.businessinsider.comEQS-News: AT&S 2024/25 on growth course againMay 13, 2024 | msn.comAuckland deputy mayor Desley Simpson urges AT to consult over parking chargesMay 13, 2024 | msn.comTransport Minister backs mayor, says AT needs 'greater accountability' after CBD parking hikeMay 8, 2024 | msn.com‘Disturbing and Very Unusual': Authorities Seek Info in Hunt for Spiked Dog Treat Perpetrator on ATMay 8, 2024 | msn.comTHURSDAY AT 6 ON KATU NEWS: Portland problems hinder American Dream for restaurant ownersMay 3, 2024 | msn.comAdidas Terrex's Hydroterra AT Hiking Sandal Is Built for Water and the TrailMay 2, 2024 | msn.comTHURSDAY AT 6 ON KATU NEWS: Neighbors question city's progress on homeless encampmentsApril 30, 2024 | finance.yahoo.comPARTY CITY SPONSORS FIRST-EVER THE GREAT LOMBABY GAMES AT 'NEW HEIGHTS LIVE' HOSTED BY JASON AND TRAVIS KELCEApril 30, 2024 | msn.comToyota launches Rumion G AT variant in India, starting at Rs 13 lakhApril 30, 2024 | msn.comAT phasing out raised crossings after community angerApril 29, 2024 | msn.comToyota Rumion G AT variant launched in India at Rs. 13 lakhApril 26, 2024 | msn.comLSU Gymnastics National Championship parade, celebrationApril 25, 2024 | msn.comTHRUSDAY AT 6 ON KATU NEWS| Nightly fuel thefts plague U-HAUL rental locationsApril 25, 2024 | msn.comWATCH LIVE TONIGHT AT 6 P.M. : LSU Gymnastics National Championship parade, celebrationApril 24, 2024 | finance.yahoo.comOPERATION HOPE CEO JOHN HOPE BRYANT'S LATEST BOOK, 'FINANCIAL LITERACY FOR ALL,' DEBUTS AT #12 ON USA TODAY BESTSELLER LISTApril 17, 2024 | finance.yahoo.comFREE CHICKEN SALAD FOR MOMS THIS MOTHER'S DAY AT CHICKEN SALAD CHICKApril 16, 2024 | finance.yahoo.comLIGHTING THE WAY FORWARD AT "THE CRADLE OF HUMANKIND" IN DESTINATION: SCIENTOLOGY, JOHANNESBURGApril 16, 2024 | msn.comTONIGHT AT 6: An incredible update on Vicky, the disabled woman living on the side of I-5April 9, 2024 | finance.yahoo.comGACA: GLOBAL AVIATION LEADERS TO ADDRESS AVIATION CHALLENGES AND OPPORTUNITIES AT 2024 FUTURE AVIATION FORUM IN RIYADH, MAY 20-22April 8, 2024 | msn.comLEGO's AT-AT set gets price cut in time-limited dealMarch 26, 2024 | finance.yahoo.comHAPPY HOPPY HOLIDAY AT GALAXY MACAU WITH EGGS-TRA SPECIAL EASTER MENUSMarch 20, 2024 | msn.comNokian Outpost AT long-term wrap-up: Decent tires, snow or noSee More Headlines Receive AGYTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/02/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:AGYTF Previous SymbolNASDAQ:AGYTF CUSIPN/A CIKN/A Webwww.allergytherapeutics.com Phone44-19-0384-4700FaxN/AEmployees600Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$73.41 million Price / Sales0.19 Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-2.00Miscellaneous Outstanding Shares688,950,000Free FloatN/AMarket Cap$13.78 million OptionableNot Optionable Beta518.72 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Manuel Llobet (Age 57)CEO & Exec. Director Comp: $683.78kMr. Nicolas Alexander Ulrich Wykeman (Age 56)CFO & Exec. Director Comp: $392.3kMs. Beverly LeesGroup Operations DirectorDr. Murray SkinnerChief Scientific OfficerMr. Santiago PuigBus. Devel. DirectorMs. Sue BakerHead of HRSimon PiggottHead of Clinical ScienceAlan BullimoreHead of Communication & Market Devel.Mr. Russell PicketGroup Financial ControllerSara GoldsbroughCompany Sec.More ExecutivesKey CompetitorsTotal BrainOTCMKTS:BRRZYVoyager DigitalOTCMKTS:VYGVFWolford AktiengesellschaftOTCMKTS:WLFDYParkson Retail GroupOTCMKTS:PKSGYElse NutritionOTCMKTS:BABYFView All Competitors This page (OTCMKTS:AGYTF) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.